Format

Send to

Choose Destination
Angew Chem Int Ed Engl. 2004 Jun 14;43(24):3118-33.

A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?

Author information

1
Département Cardiovasculaire/Thrombose, Sanofi-Synthélabo, 195 route d'Espagne, 31036 Toulouse cedex, France. maurice.petitou@sanofi-synthélabo.com

Abstract

Heparin is a sulfated glycosaminoglycan isolated from animal organs that has been used clinically as an antithrombotic agent since the 1940s. In the early 1980s it was discovered that a unique pentasaccharide domain in some heparin chains activates antithrombin III (AT-III), a serine protease inhibitor that blocks thrombin and factor Xa in the coagulation cascade. Sanofi-Synthélabo and Organon developed a synthetic analogue of this pentasaccharide. The resulting antithrombotic drug arixtra, which went on the market in the USA and Europe in 2002, shows superior antithrombotic activity and brings about AT-III-mediated activity against factor Xa exclusively. Structure-based design has subsequently led to analogues with longer-lasting activity, such as idraparinux, as well as novel conjugates and long oligosaccharides with specific anti-Xa and antithrombin activities. The new drug candidates are more selective in their mode of action than heparin and less likely to induce thrombocytopenia.

PMID:
15199558
DOI:
10.1002/anie.200300640
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center